Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds

Amarantus BioScience Holdings, Inc.10 enrolled

Overview

The purpose of this research study is to test how well the investigational treatment, Engineered Skin Substitutes (ESS-W), works for covering and treating burn wounds. The areas of the body that are treated with ESS-W will be compared to similar areas treated with the patient's own skin (split-thickness skin autograft (AG)). A skin autograft (AG) will be performed by taking healthy skin from one area of the body and placing it on the burned area.

This study is designed to evaluate the safety and efficacy of autologous engineered skin substitute (ESS-W) compared to conventional split-thickness AG for the treatment of extensive, deep partial- and full-thickness thermal burns. A matched and randomized burn site format will be used to evaluate the successful graft take on excised deep partial- and full-thickness burns when grafted with either 1) unmeshed ESS-W or 2) meshed AG (the current standard treatment of split thickness AG). This research study is divided into five study periods: (1) Screening Period of up to one week and (2) Pre-Grafting Period, which will last approximately 35-45 days, (3) Grafting Day(s), which are the day(s) on which grafts are applied (i.e., First Graft: Day 0 and the optional subsequent Grafting Day i.e., Second Graft: Day 0), (4) Post Grafting Observation Period, which begins with 28 days follow-up after each Grafting Day(s), and continues till Post-Operative Month (POM) 6 from the last Grafting Day, and (5) Anecdotal Observation Period

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Thermal Injury

Interventions

Autologous Engineered Skin SubstituteDRUG

The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG. ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place.

Split-Thickness Autograft (AG)DRUG

The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG. The AG regimen occurs in stages, beginning with excision of the burned skin, followed by temporary wound coverage (e.g. cadaveric skin allografts, porcine xenograft, synthetic or biologic dressings or medical devices) to achieve wound homeostasis, and completed by permanent wound closure using autologous skin.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Has deep partial or full-thickness thermal burns ≥50% of the TBSA and fulfills the total grafting area requirement ranging from 288 cm2 up to 5,600 cm2, divided between two (or more) recipient sites. * Is expected to require multiple skin grafting procedures. * Is ≥18 years and ≤40 years of age at the time of enrollment. * Females of childbearing potential must have a negative pregnancy test prior to enrollment and agree to use appropriate birth control methods during the pre-grafting period and for three months following the last Grafting Day. * Subject (or a legally authorized representative (LAR)) has provided written informed consent for study participation and procedures to be performed. Exclusion Criteria: * Has a current diagnosis of septic shock or Multiple Organ Dysfunction Syndrome, which in the opinion of the Investigator would put the potential subject at risk of serious morbidity or death by participating in the study. * Has a current diagnosis of an invasive burn wound infection in unexcised burn wound. * Is pregnant. * Is a prisoner at the time of obtaining written informed consent. * Has a documented history of allergy or sensitivity to any of the antimicrobials or reagents used in preparation and application of ESS-W including the irrigation solution used before and after grafting. These include aminoglycosides, polymyxin B, mupirocin, ciprofloxacin, amphotericin B, hydrocortisone, and insulin. * Has a documented history of allergy or sensitivity to any of the animal products used in preparation of ESS-W. These products include bovine blood, bovine collagen, bovine collagenase, and porcine trypsin-versene. * Has a documented history of allergy or sensitivity to glycosaminoglycan, the polymer component of ESS-W. * Has a documented ongoing condition which could delay wound healing such as insulin-dependent diabetes mellitus, Cushing syndrome or disease, scurvy, chronic hypothyroidism, congenital or acquired immunosuppressive condition, chronic renal failure, or chronic hepatic dysfunction (Child-Pugh class B or C). * Has a severe malnutrition or other concomitant illness which, in the opinion of the Investigator, has the potential to significantly delay wound healing.

Locations (3)

Arizona Burn Center

Pheonix, Arizona, United States

US Army Institute of Surgical Research

Houston, Texas, United States

Harborview Medical Center

Seattle, Washington, United States

Outcomes

Primary Outcomes

Incidence and severity of infections at grafting sites

Assessments will be done on the following days/months: * Post operative Day 1 - Day 6, Day 7, Day 14 and Day 28 after each grafting day. * Post Operative Month 3 and Month 6 after the last grafting day.

Time frame: Up to Month 6 after the last grafting day

Incidence of re-grafting

Assessments will be done on the following days/months: * Post operative Day 7, Day 14 and Day 28 after each grafting day. * Post Operative Month 3 and Month 6 after the last grafting day.

Time frame: Up to Month 6 after the last grafting day

Incidence of adverse events that are related to study treatment and associated with the grafting site

Assessments will be done on the following days/months: * Post operative Day 1 - Day 6, Day 7, Day 14 and Day 28 after each grafting day. * Post Operative Month 3, Month 6, Month 12, Month 24 and Month 36 after the last grafting day

Time frame: Up to Month 36 after the last grafting day

Incidence of all adverse events.

Time frame: Up to Month 36 after the last grafting day

Percentage engraftment as determined by the Investigator through clinical assessment

Assessments will be done on the following days/months: * Post operative Day 14 and Day 28 after each grafting day. * Post Operative Month 3 after the last grafting day

Time frame: Up to Month 3 after the last grafting day

Percentage engraftment as determined by an independent observer through clinical assessment

Assessments will be done on the following days/months: * Post operative Day 14 and Day 28 after each grafting day. * Post Operative Month 3 after the last grafting day

Time frame: Up to Month 3 after the last grafting day

Confirmation of engraftment by histological assessment

Assessments will be done on the following days/months: \- Post Operative Month 3 and Month 6 after the last grafting day

Time frame: Up to Month 6 after the last grafting day

Percentage of wound closure as determined by blinded computerized planimetric assessment

Assessments will be done on the following days/months: * Post operative Day 14 and Day 28 after each grafting day. * Post Operative Month 3 after the last grafting day

Time frame: Up to Month 3 after the last grafting day

Percentage area of re-grafting as determined by blinded computerized planimetric assessment

Assessments will be done on the following days/months: * Post operative Day 7, Day 14 and Day 28 after each grafting day. * Post Operative Month 3 and Month 6 after the last grafting day.

Time frame: Up to Month 6 after the last grafting day

Secondary Outcomes

Scar outcome assessment using the modified Vancouver Scar Scale (mVSS).

Assessments will be done on the following days/months: * Post operative Day 28 after each grafting day. * Post Operative Month 3, Month 6, Month 12, Month 24 and Month 36 after the last grafting day

Time frame: Up to Month 36 after the last grafting day

Incidence and severity of post-burn pruritus utilizing a validated patient self-assessment instrument

Assessments will be done on the following days/months: * Post operative Day 14 and Day 28 after each grafting day. * Post Operative Month 3, Month 6, Month 12, Month 24 and Month 36 after the last grafting day

Time frame: Up to Month 36 after the last grafting day

Incidence of contracture release or revision surgeries

Assessments will be done on the following days/months: \- Post Operative Month 3, Month 6, Month 12, Month 24 and Month 36 after the last grafting day

Time frame: Up to Month 36 after the last grafting day

Incidence of increased temperature sensitivity

Assessments will be done on the following days/months: \- Post Operative Month 3, Month 6, Month 12, Month 24 and Month 36 after the last grafting day

Time frame: Up to Month 36 after the last grafting day

Incidence of paresthesias, pain, dulling of sensation assessed through patient self-reporting scale and by monofilament testing

Assessments will be done on the following days/months: \- Post Operative Month 3, Month 6, Month 12, Month 24 and Month 36 after the last grafting day

Time frame: Up to Month 36 after the last grafting day

Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds

Overview

Conditions

Interventions

Eligibility

Locations (3)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts